Inside Precision Medicine November 30, 2022
Genomenon has announced a partnership with rare neuro-disease orgs COMBINEDBrain, SynGAP, and SLC-6A1 Connect. Along with pharma partners, the team aim to accelerate the development of precision drugs to treat rare neurodevelopmental disorders.
“We are honored to collaborate with COMBINEDBrain, SynGAP Research Fund, and SLC6A1 Connect,” said Mike Klein, CEO of Genomenon. “By putting critical information at the fingertips of researchers and clinicians seeking diagnoses for their patients, this new venture represents a shared mission to ensure that no patient goes undiagnosed or untreated.”
Although rare diseases comprise most of the world’s smallest drug markets, they also include some of the most expensive treatments in the world, including the just-approved Hemgenix (CSL) for hemophilia B, which reportedly costs $3.5 million...
Today's Sponsors
Today's Sponsor